Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Portfolio Pulse from
Alnylam Pharmaceuticals announced promising interim Phase 1 data for its RNAi therapeutic, nucresiran, showing rapid and sustained knockdown of TTR at six months post a single dose. The results were presented at the American Heart Association Scientific Sessions 2024.
November 17, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals presented positive interim Phase 1 data for nucresiran, indicating effective TTR knockdown sustained for six months after a single dose. This could enhance investor confidence in Alnylam's pipeline and future prospects.
The positive interim data from the Phase 1 study of nucresiran suggests strong efficacy in TTR knockdown, which is crucial for treating ATTR amyloidosis. This development could lead to increased investor confidence in Alnylam's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100